<a href="https://laohu8.com/S/FEMY">Femasys Inc</a>. reports nine-month sales of $1.48 million and net loss of $14.68 million
Femasys Inc. reported sales of $1.5 million for the nine months ended September 30, 2025, an increase of 41.3% from $1.0 million in the same period of 2024, driven by sales of FemBloc and FemVue. Research and development expenses decreased 4.7% to $5.8 million from $6.0 million. Net loss for the period was $14.7 million, or ($0.46) per share, compared to a net loss of $13.7 million, or ($0.62) per share, for the prior year period. Cash and cash equivalents totaled $4.6 million at the end of September 2025, up from $3.5 million at the end of 2024. Business developments included a second partner order for FemBloc in Europe, FDA approval to continue the final phase of the FemBloc FINALE trial, and a $12 million financing agreement with potential total funding of $58 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576107-en) on November 14, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。